Provided by Tiger Fintech (Singapore) Pte. Ltd.

INCANNEX HEALTHCARE LTD

0.5250
-0.0550-9.48%
Post-market: 0.5242-0.0008-0.15%17:05 EDT
Volume:50.26M
Turnover:26.79M
Market Cap:49.19M
PE:-0.43
High:0.5600
Open:0.5596
Low:0.5063
Close:0.5800
52wk High:3.12
52wk Low:0.0800
Shares:93.70M
Float Shares:89.88M
Volume Ratio:0.78
T/O Rate:55.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2121
EPS(LYR):-1.1420
ROE:-201.88%
ROA:-76.74%
PB:6.64
PE(LYR):-0.46

Loading ...

US Listed Shares of Incannex Healthcare Rise 18.7% After Co's Anxiety Treatment Meets Mid-Stage Trial Goal

THOMSON REUTERS
·
Aug 26

Incannex Healthcare Announces Positive Phase 2 Trial Results for Psilocybin-Assisted Therapy PSX-001 in Treating Generalised Anxiety Disorder

Reuters
·
Aug 26

Incannex Healthcare Inc - PSI-Gad Treatment Well Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
Aug 26

Incannex Healthcare: Phase 2 PSI-Gad Trial Shows Significant Improvements Across All Primary & Secondary Endpoints

THOMSON REUTERS
·
Aug 26

Incannex Healthcare Inc - Psx-001 Shows Significant Improvements in Gad Treatment

THOMSON REUTERS
·
Aug 26

Incannex Reports Positive Results From Phase 2 Clinical Trial of Psx-001 (PSI-Gad) for Generalised Anxiety Disorder

THOMSON REUTERS
·
Aug 26

Top Midday Gainers

MT Newswires Live
·
Aug 23

Incannex Healthcare Shares Rise 32.8% Premarket on $20 Million Share Repurchase Program

THOMSON REUTERS
·
Aug 22

BUZZ-Incannex Healthcare jumps on $20 million share repurchase program

Reuters
·
Aug 22

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

THOMSON REUTERS
·
Aug 22

Stonegate Updates Coverage: Incannex Healthcare Achieves Significant Progress with IHL-42X in Phase 2 Trial

Reuters
·
Aug 20

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for Ihl-42X in Obstructive Sleep Apnoea

THOMSON REUTERS
·
Aug 08

Incannex Healthcare Inc - 57.6% Participants Report Improvement in Obstructive Sleep Apnoea

THOMSON REUTERS
·
Aug 08

Incannex Healthcare Inc - Ihl-42X Well Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
Aug 08

Incannex Healthcare Inc - Maximum Ahi Reductions up to 83% for High-Dose Group

THOMSON REUTERS
·
Aug 08

Incannex Healthcare Announces Promising Phase 2 Results for IHL-42X, Highlighting Significant Improvements in Sleep and Cognitive Function for OSA Patients

Reuters
·
Aug 08

BRIEF-Incannex Healthcare Confirms Strong Cash Position No Plans Or Requirement To Fully Utilise ATM In Near Term

Reuters
·
Jul 31

Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise Atm in Near Term

THOMSON REUTERS
·
Jul 31

Incannex reports results from RePOSA Phase 2 trial of IHL-42X

TIPRANKS
·
Jul 30

Incannex Healthcare Unveils Promising Phase 2 Trial Results for IHL-42X, Paving Way for Potential Breakthrough in Sleep Apnea Treatment

Reuters
·
Jul 30